SCHEMBL434231

SCHEMBL434231

NC(=O)CCc1ccc(OCc2ccc(OCC(=O)c3ccccc3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 7/20 0.59
FFAR4 Q5NUL3 3/20 0.59
PARP10 Q53GL7 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
MAPT P10636 2/20 0.53
RAB9A P51151 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HTT P42858 2/20 0.53
GAA P10253 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.50
PLA2G4B P0C869 1/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
MAPK1 P28482 1/20 0.50
CASP3 P42574 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
CES1 P23141 1/20 0.49
EGFR P00533 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL433667 0.89 FFAR1 (0.76) FFAR1FFAR4SMN1; SMN2MAPTRAB9A
SCHEMBL2170636 0.87 FFAR1 (0.77) FFAR1FFAR4PARP10
SCHEMBL2036020 0.86 FFAR1 (0.76) FFAR1FFAR4PARP10MAPTALDH1A1
SCHEMBL432798 0.85 RAB9A (0.58) FFAR1FFAR4SMN1; SMN2MAPTRAB9A
SCHEMBL9787125 0.84 PLA2G4B (0.67) PARP10SMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL22664707 0.83 FFAR1 (0.74) FFAR1FFAR4PARP10SMN1; SMN2MAPT
SCHEMBL435107 0.82 FFAR1 (0.64) FFAR1FFAR4PARP10SMN1; SMN2MAPT
SCHEMBL15248956 0.82 FFAR1 (0.64) FFAR1FFAR4PARP10SMN1; SMN2MAPT
SCHEMBL435106 0.82 FFAR1 (0.64) FFAR1FFAR4PARP10SMN1; SMN2MAPT
SCHEMBL12473736 0.81 SMN1; SMN2 (0.52) FFAR1FFAR4SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 FFAR1 24/4885FFAR4 26/4885PARP10 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.